10X Genomics has purchased genomic analysis platform Spatial Transcriptomics, based on research at Karolinska Institute and KTH Royal Institute of Technology.
Spatial Transcriptomics, a Sweden-based spatial genomic analysis spinout of Karolinska Institute and KTH Royal Institute of Technology, was acquired by DNA sequencing firm 10X Genomics on Monday.
Financial terms of the transaction have not been disclosed.
Spatial Transcriptomics has created a spatial genomics platform that applies microscopy and RNA sequencing to tissue samples to build morphological 2D images of the relationship between cells and the contents of individual cells.
The approach is intended to drive advances in biology and medical areas such as oncology, neurology and immunology by rendering a spatial diagram of gene expression, where outputs such as proteins are created from genetic instructions.
Spatial claims its technology is the first to be capable of capturing such information from all active genes in each tissue. By using sequencing standards already employed by research laboratories, Spatial also hopes to offer its clients an interoperable workflow.
10X Genomics views the deal as further enhancement for its portfolio of DNA sequencing technologies following the purchase of Stanford epigenomics services spinout Epinomics for an undisclosed sum in August 2018.
The firm expects to collaborate closely with Spatial’s founding team and will expand the spinout’s offices in Stockholm, Sweden following the transaction.
Spatial Transcriptomics does not appear to have previously disclosed details of equity funding.
